樂觀
$211.45
情境價格
$364.820
+2.408 (+0.66%)收盤時
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.
RBC Capital
$390
2026-08-07
RBC Capital
2026-08-07
目標價
$390
Wells Fargo
$310
2026-05-25
Wells Fargo
2026-05-25
目標價
$310
RBC Capital
$320
2026-05-14
RBC Capital
2026-05-14
目標價
$320
Wells Fargo
$290
2026-05-01
Wells Fargo
2026-05-01
目標價
$290
Citi
$300
2026-04-07
Citi
2026-04-07
目標價
$300
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Bio-Rad CFO to Participate in Healthcare Forum

Bio-Rad CFO to Participate in Healthcare Conference

GraftAssureDx Advances Toward FDA Marketing Authorization

Bio-Rad Laboratories Q2 2026 Earnings Call Insights

Bio-Rad Q2 Earnings Exceed Expectations
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.
4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.

Didn't do anything, just went to the bathroom, and when I came back the chart had already done the work for me. When the market dumped early on, $BIO's bounce looked weak no matter how you read it. Every step down from the high came with volume, but the rebound kept getting lighter. Overhead trapped positions were pressing down clearly, funds just wanted to use the bounce to exit, nobody really wanted to buy. I was watching the short direction at 0.03161, with protection set at the upper edge of the bounce platform. At the time I only reminded one thing: don't try to catch a bounce in the early stage of a breakdown. If your hands are itching, go to the bathroom and wash your face. Came back and refreshed, price had already reached 0.02549, position return sitting at +1376.01%. Everyone on board should be feeling good. I took 80% off the table first, moved protection on the remaining 20% to breakeven. If it keeps dropping, let it drop, if it breaks the previous low there's another leg to capture; if it bounces back, this trade won't turn from profit into loss. Risk control done upfront is called being rational; cutting after losses is called cutting your losses. Don't chase shorts now, wait for a bounce to a structural level before acting. If the next shot doesn't come, wait patiently. The market won't only open its door once. $ADA $ETH
展開
I was about to go vent on the forum, then I checked my balance and decided to let it go. The market is always right 😮💨 When the morning session dumped, $BIO bounced and it actually looked decent for a moment. But the more I watched the order book, the more something felt off. Every push up came with no volume, a classic sign of weak follow-through. That kind of bounce looks lively, but nobody is actually stepping in to buy. The chart keeps teaching you lessons, most people just choose to sleep through class. I went ahead and opened a short at 0.03161. Someone said I was late to the trade. I didn't bother arguing, just waited for the result. Price just dropped to 0.02504, and my position PnL hit +1479.26%. It was slow at first, but once it moved, it really moved. Feels good. Nailing the rhythm matters more than anything 😎 I took 80% off the table and moved my stop on the remaining 20% back to breakeven. Whether it bounces from here or keeps grinding down, I won't be stressed either way. The prerequisite for compounding is staying alive. The shortcut to getting rich is usually going to zero. I'd rather miss a limit-up than try to catch a falling knife and end up with bloody hands. Don't chase here. Chasing at key levels is how you get hurt. I'll wait for the next signal. $XRP $LAB
展開
I opened the charts this morning, rubbed my eyes, and gave myself a little slap to make sure I wasn't seeing things. No trades, no analysis, just pure luck and stubbornness. Saying that record out loud feels embarrassing, but honestly, it feels great. Panic comes from having no plan, losses come from overthinking. I just sat there quietly watching it perform. When the screen was full of green, some people were panicking, but I found it interesting. Thinking back to a few days ago, the last look before bed, the trend clearly had no strength, the bounce was weak, and volume wasn't following at all. Funds wanted to push it up, but even they didn't dare enter. The fake breakout smell was right in your face. My only thought at the time was that this kind of bounce wouldn't last past the third watch. Short above 0.03161, now $BIO is at 0.02458, unrealized gain +1573.54%. This one was just the market in a good mood, handing money over. But even with the win, position management still matters. Everyone note the position moves: take profit on 80% first to lock in gains, move the stop on the remaining 20% to near cost, and let it run a bit. Risk control done upfront is called being rational; cutting after a loss is called a last resort. Don't get jealous of this level now, this isn't the time to chase. If you missed the rhythm, you missed it. Wait for a more comfortable spot next round. I'll keep watching the charts and call it as soon as there's a signal. The market never lacks opportunities, it lacks the patience to wait. Everyone keep your hands tied. $SNDK $SOL
展開本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。